-- Data support ongoing development of
antibody-drug conjugate (ADC) program targeting HER3-expressing
cancers –
-- On-track to nominate development candidate
in 2024 --
BOSTON, March 5,
2024 /PRNewswire/ -- Elevation Oncology, Inc.
(Nasdaq: ELEV), an innovative oncology company focused on the
discovery and development of selective cancer therapies to treat
patients across a range of solid tumors with significant unmet
medical need, today announced that it will present preclinical
proof-of-concept data for its differentiated HER3-targeting
antibody-drug conjugate (ADC) program in a poster session at the
American Association for Cancer Research (AACR) Annual Meeting
2024, being held April 5-10 in San Diego, California.
"We are excited to share preclinical proof-of-concept data for
our HER3-ADC program. HER3 is a clinically validated oncology and
ADC target, which is overexpressed across a range of solid tumors,
and is often associated with a poor clinical outcome," said
David Dornan, Ph.D., Chief
Scientific Officer of Elevation Oncology. "At AACR, we plan to
share preclinical proof-of-concept data highlighting our progress
towards the development of a differentiated HER3-ADC. We look
forward to nominating a development candidate this year and to the
advancement of our HER3-ADC program toward the clinic, with the
goal of improving patient outcomes."
Details of the poster presentation at AACR 2024 are as
follows:
Title: Therapeutic potential of a HER3 antibody-drug
conjugate for the treatment of HER3-expressing cancers
- Abstract: #3121
- Session Category: Experimental and Molecular
Therapeutics
- Session Title: Antibody-Drug Conjugates
- Session Date and Time: Monday,
April 8, from 1:30 p.m. to 5 p.m.
PT
About Elevation Oncology, Inc.
Elevation Oncology is
an innovative oncology company focused on the discovery and
development of selective cancer therapies to treat patients across
a range of solid tumors with significant unmet medical needs. We
are rethinking drug development by seeking out innovative,
selective cancer therapies that can be matched to a patient's
unique tumor characteristics. Our lead candidate, EO-3021, is a
potential best-in-class antibody drug conjugate (ADC) designed to
target Claudin 18.2, a clinically validated oncology target.
EO-3021 selectively delivers a cytotoxic payload directly to cancer
cells expressing Claudin 18.2. We are evaluating EO-3021 in a Phase
1 study in patients with advanced, unresectable or metastatic solid
tumors likely to express Claudin 18.2 including gastric,
gastroesophageal junction, pancreatic or esophageal cancers. We are
also exploring other opportunities through new or existing
partnerships and business development opportunities to expand our
oncology pipeline. For more information, visit
www.ElevationOncology.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, anticipated clinical and preclinical
development activities, expected timing of announcements, potential
benefits of Elevation Oncology's product candidates, potential
market opportunities for Elevation Oncology's product candidates
and the ability of Elevation Oncology's product candidates to treat
their targeted indications. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. These forward-looking statements may be accompanied by
such words as "aim," "anticipate," "believe," "could," "estimate,"
"expect," "forecast," "goal," "intend," "may," "might," "plan,"
"possible," "potential," "will," "would," and other words and terms
of similar meaning. Although Elevation Oncology believes that the
expectations reflected in such forward-looking statements are
reasonable, Elevation Oncology cannot guarantee future events,
results, actions, levels of activity, performance or achievements,
and the timing and results of biotechnology development and
potential regulatory approval are inherently uncertain.
Forward-looking statements are subject to risks and uncertainties
that may cause Elevation Oncology's actual activities or results to
differ significantly from those expressed in any forward-looking
statement, including risks and uncertainties related to Elevation
Oncology's ability to advance its product candidates, the timing
and results of preclinical studies and clinical trials, approvals
and commercialization of product candidates, the receipt and timing
of potential regulatory designations, Elevation Oncology's ability
to fund development activities and achieve development goals,
Elevation Oncology's ability to protect intellectual property,
Elevation Oncology's ability to establish and maintain
collaborations with third parties, and other risks and
uncertainties described under the heading "Risk Factors" in
documents Elevation Oncology files from time to time with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date of this press release, and
Elevation Oncology undertakes no obligation to revise or update any
forward-looking statements to reflect events or circumstances after
the date hereof.
Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor
Relations
cmasse@elevationoncology.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-preclinical-proof-of-concept-data-for-her3-adc-program-at-the-american-association-for-cancer-research-aacr-annual-meeting-2024-302080621.html
SOURCE Elevation Oncology